[
  {
    "title": "昭衍新药拟投资5000万美元支持间接全资子公司Biomere 用于扩大再生产和日常运营",
    "href": "http://stock.jrj.com.cn/2022/12/30203137250975.shtml",
    "datetime": "2022-12-30 20:31:26",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东左从林减持59万股 套现3119.92万 2022年前三季度公司净利6.32亿",
    "href": "http://stock.jrj.com.cn/2022/12/28195137244158.shtml",
    "datetime": "2022-12-28 19:51:21",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东顾晓磊减持327.3万股 套现1.75亿 2022年前三季度公司净利6.32亿",
    "href": "http://stock.jrj.com.cn/2022/12/21205137229549.shtml",
    "datetime": "2022-12-21 20:51:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药3名股东合计减持409.61万股 套现2.53亿 2022年前三季度公司净利6.32亿",
    "href": "http://stock.jrj.com.cn/2022/11/22205037158834.shtml",
    "datetime": "2022-11-22 20:50:35",
    "code": "603127"
  },
  {
    "title": "港股股东不同意，昭衍新药拟推5584万元股权激励计划折戟",
    "href": "http://stock.jrj.com.cn/2022/11/18152637149850.shtml",
    "datetime": "2022-11-18 15:26:14",
    "code": "603127"
  },
  {
    "title": "昭衍新药高级管理人员及股东合计减持7.39万股 套现523万 2022年前三季度公司净利6.32亿",
    "href": "http://stock.jrj.com.cn/2022/11/02201137107746.shtml",
    "datetime": "2022-11-02 20:11:53",
    "code": "603127"
  },
  {
    "title": "港股异动 | 昭衍新药涨11% 获瑞银增持95.96万股",
    "href": "http://stock.jrj.com.cn/2022/10/26100737084645.shtml",
    "datetime": "2022-10-26 10:07:52",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)高开超6% 料首三季赚最多6.5亿元",
    "href": "http://stock.jrj.com.cn/2022/10/19092637065912.shtml",
    "datetime": "2022-10-19 09:26:49",
    "code": "603127"
  },
  {
    "title": "昭衍新药2022年前三季度预计净利6.07亿-6.57亿同比增加145%-165% 在手订单顺利交付",
    "href": "http://stock.jrj.com.cn/2022/10/18213237065278.shtml",
    "datetime": "2022-10-18 21:32:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药：前三季度净利同比预增144.8%-164.8%",
    "href": "http://stock.jrj.com.cn/2022/10/18190537064860.shtml",
    "datetime": "2022-10-18 19:05:36",
    "code": "603127"
  },
  {
    "title": "昭衍新药：预计前三季度净利同比增加约145%-165%",
    "href": "http://stock.jrj.com.cn/2022/10/18185137064827.shtml",
    "datetime": "2022-10-18 18:51:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：前三季度净利预增144.8%-164.8%",
    "href": "http://stock.jrj.com.cn/2022/10/18184837064808.shtml",
    "datetime": "2022-10-18 18:48:59",
    "code": "603127"
  },
  {
    "title": "昭衍新药高管股东已减持套现超7亿 高增长背后存在“隐患”？",
    "href": "http://stock.jrj.com.cn/2022/09/30090437033223.shtml",
    "datetime": "2022-09-30 09:04:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127)本次限售股上市日为2022年9月14日",
    "href": "http://stock.jrj.com.cn/2022/09/07194736981286.shtml",
    "datetime": "2022-09-07 19:47:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药2022年上半年营利同比双增",
    "href": "http://stock.jrj.com.cn/2022/08/31165036958468.shtml",
    "datetime": "2022-08-31 16:50:17",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)半年度扣非净利润3.45亿元、同比增长166.79%",
    "href": "http://stock.jrj.com.cn/2022/08/30224636955103.shtml",
    "datetime": "2022-08-30 22:46:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年净利润3.71亿元 同比增141.4%",
    "href": "http://stock.jrj.com.cn/2022/08/30195836954211.shtml",
    "datetime": "2022-08-30 19:58:09",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：拟推2022年A股限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/08/15182536901195.shtml",
    "datetime": "2022-08-15 18:25:25",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)拟推2022年A股员工持股计划 筹资总额上限为494.388万元",
    "href": "http://stock.jrj.com.cn/2022/08/15182336901197.shtml",
    "datetime": "2022-08-15 18:23:49",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)2021年度A股权益分派10转4派3.6元、股权登记日为8月5日",
    "href": "http://stock.jrj.com.cn/2022/08/01170736859565.shtml",
    "datetime": "2022-08-01 17:07:21",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年预计净利同比增约121.8%到161.8%",
    "href": "http://stock.jrj.com.cn/2022/07/14164136811494.shtml",
    "datetime": "2022-07-14 16:41:47",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)半年度净利润预增121.8%到161.8%",
    "href": "http://stock.jrj.com.cn/2022/07/14163936811479.shtml",
    "datetime": "2022-07-14 16:39:35",
    "code": "603127"
  },
  {
    "title": "昭衍新药将花不超800万元回购公司股份 用于员工持股计划",
    "href": "http://stock.jrj.com.cn/2022/07/07205236792222.shtml",
    "datetime": "2022-07-07 20:52:49",
    "code": "603127"
  },
  {
    "title": "核心业务毛利率走低！“猴茅”昭衍新药溢价收购两公司为哪般？",
    "href": "http://stock.jrj.com.cn/2022/07/04164336780117.shtml",
    "datetime": "2022-07-04 16:43:20",
    "code": "603127"
  },
  {
    "title": "CRO概念股持续走强 昭衍新药午后涨停",
    "href": "http://stock.jrj.com.cn/2022/07/04133336779458.shtml",
    "datetime": "2022-07-04 13:33:49",
    "code": "603127"
  },
  {
    "title": "【龙虎榜】昭衍新药6月20日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/06/20181136743668.shtml",
    "datetime": "2022-06-20 18:11:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药：玮美生物已完成工商变更，成为公司全资子公司",
    "href": "http://stock.jrj.com.cn/2022/06/16142636734272.shtml",
    "datetime": "2022-06-16 14:26:00",
    "code": "603127"
  },
  {
    "title": "港股异动丨昭衍新药AH齐涨 完成收购玮美生物100%股权",
    "href": "http://stock.jrj.com.cn/2022/06/16132536734099.shtml",
    "datetime": "2022-06-16 13:25:15",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：完成收购玮美生物100%股权",
    "href": "http://stock.jrj.com.cn/2022/06/15223136732725.shtml",
    "datetime": "2022-06-15 22:31:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：玮美生物完成股权转让相关工商变更登记备案手续",
    "href": "http://stock.jrj.com.cn/2022/06/15173736731608.shtml",
    "datetime": "2022-06-15 17:37:13",
    "code": "603127"
  },
  {
    "title": "“疯狂的猴子”如何让昭衍新药三个月“躺赚”3800万？",
    "href": "http://stock.jrj.com.cn/2022/06/14203436728966.shtml",
    "datetime": "2022-06-14 20:34:05",
    "code": "603127"
  },
  {
    "title": "昭衍新药高级管理人员于爱水减持5700股 套现68.34万 2021年公司净利5.57亿",
    "href": "http://stock.jrj.com.cn/2022/06/10211336720703.shtml",
    "datetime": "2022-06-10 21:13:10",
    "code": "603127"
  },
  {
    "title": "一只猴子16万元！多家龙头药企“囤猴”，价格4年飙涨10倍",
    "href": "http://stock.jrj.com.cn/2022/06/09170736716187.shtml",
    "datetime": "2022-06-09 17:07:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获APG Asset Management N.V.增持6.59万股",
    "href": "http://stock.jrj.com.cn/2022/06/09062236714380.shtml",
    "datetime": "2022-06-09 06:22:41",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事顾晓磊及其一致行动人拟提前终止减持计划 其尚未减持股份",
    "href": "http://stock.jrj.com.cn/2022/06/08163536712582.shtml",
    "datetime": "2022-06-08 16:35:50",
    "code": "603127"
  },
  {
    "title": "港股异动丨昭衍新药AH齐涨 完成收购英茂生物100%股权",
    "href": "http://stock.jrj.com.cn/2022/06/07094536708014.shtml",
    "datetime": "2022-06-07 09:45:44",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获Aggregate of abrdn plc增持11.58万股",
    "href": "http://stock.jrj.com.cn/2022/06/07063036707554.shtml",
    "datetime": "2022-06-07 06:30:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：减持数过半 冯宇霞、周志文已合计减持412.77万股",
    "href": "http://stock.jrj.com.cn/2022/05/27184736685573.shtml",
    "datetime": "2022-05-27 18:47:22",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东孙辉业减持3.37万股 套现337.1万 2021年公司净利5.57亿",
    "href": "http://stock.jrj.com.cn/2022/05/26191136682119.shtml",
    "datetime": "2022-05-26 19:11:05",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：监事孙辉业拟提前终止减持计划 已减持3.37万股",
    "href": "http://stock.jrj.com.cn/2022/05/26165536681404.shtml",
    "datetime": "2022-05-26 16:55:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获UBS Group AG增持4.54万股",
    "href": "http://stock.jrj.com.cn/2022/05/06063536575964.shtml",
    "datetime": "2022-05-06 06:35:57",
    "code": "603127"
  },
  {
    "title": "昭衍新药2022年首季归母净利1.25亿元，同比增长34.27%",
    "href": "http://stock.jrj.com.cn/2022/04/29151936504388.shtml",
    "datetime": "2022-04-29 15:19:15",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)一季度净利润1.25亿元 同比增长34.27%",
    "href": "http://stock.jrj.com.cn/2022/04/29144036504029.shtml",
    "datetime": "2022-04-29 14:40:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)拟9.75亿元收购玮美生物科技100%股权",
    "href": "http://stock.jrj.com.cn/2022/04/29063436499241.shtml",
    "datetime": "2022-04-29 06:34:18",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)拟8.3亿元收购英茂生物科技全部股权",
    "href": "http://stock.jrj.com.cn/2022/04/29062636499235.shtml",
    "datetime": "2022-04-29 06:26:02",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：建议采纳股份激励计划(H股)",
    "href": "http://stock.jrj.com.cn/2022/04/29061536499230.shtml",
    "datetime": "2022-04-29 06:15:49",
    "code": "603127"
  },
  {
    "title": "业绩大增 股价冲高回落 昭衍新药的高管们再减持387万股",
    "href": "http://stock.jrj.com.cn/2022/04/14082836331565.shtml",
    "datetime": "2022-04-14 08:28:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事顾晓磊及其一致行动人拟合计减持不超1.015%股份",
    "href": "http://stock.jrj.com.cn/2022/04/11163736304496.shtml",
    "datetime": "2022-04-11 16:37:19",
    "code": "603127"
  },
  {
    "title": "昭衍新药2021年净利5.57亿同比增长76.96% 董事长冯宇霞薪酬197.60万",
    "href": "http://stock.jrj.com.cn/2022/03/31165336240013.shtml",
    "datetime": "2022-03-31 16:53:29",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：2021年净利增76.96%至5.57亿元 拟10派3.6元",
    "href": "http://stock.jrj.com.cn/2022/03/31094136229617.shtml",
    "datetime": "2022-03-31 09:41:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：拟认购厦门源峰基金2亿元的基金份额",
    "href": "http://stock.jrj.com.cn/2022/03/30234836211745.shtml",
    "datetime": "2022-03-30 23:48:33",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：拟认购首都大健康5000万元的基金份额",
    "href": "http://stock.jrj.com.cn/2022/03/30234736211748.shtml",
    "datetime": "2022-03-30 23:47:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：2021年净利增76.96%至5.57亿元 拟10派3.6元",
    "href": "http://stock.jrj.com.cn/2022/03/30221336208799.shtml",
    "datetime": "2022-03-30 22:13:47",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事冯宇霞等5人减持期过半 均未减持公司股份",
    "href": "http://stock.jrj.com.cn/2022/03/14170534824411.shtml",
    "datetime": "2022-03-14 17:05:01",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持200.74万股 套现合计3.12亿 2021年公司净利5.57亿",
    "href": "http://stock.jrj.com.cn/2022/03/03183234516869.shtml",
    "datetime": "2022-03-03 18:32:47",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：减持期届满 董事孙云霞、顾晓磊累计减持共200.74万股",
    "href": "http://stock.jrj.com.cn/2022/03/03163634516178.shtml",
    "datetime": "2022-03-03 16:36:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获Aggregate of abrdn plc增持100万股",
    "href": "http://stock.jrj.com.cn/2022/03/02064234510383.shtml",
    "datetime": "2022-03-02 06:42:55",
    "code": "603127"
  },
  {
    "title": "昭衍新药2021年净利5.57亿同比增长76.83% 实验室产能利用率持续提升",
    "href": "http://stock.jrj.com.cn/2022/02/24201334453243.shtml",
    "datetime": "2022-02-24 20:13:17",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根大通增持7.95万股",
    "href": "http://stock.jrj.com.cn/2022/02/21063934417297.shtml",
    "datetime": "2022-02-21 06:39:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持23.3万股",
    "href": "http://stock.jrj.com.cn/2022/02/18070334384199.shtml",
    "datetime": "2022-02-18 07:03:19",
    "code": "603127"
  },
  {
    "title": "午评：赛道股反弹创业板指大涨2.64%，CRO概念爆发昭衍新药、凯莱英涨停",
    "href": "http://stock.jrj.com.cn/2022/02/15113234352929.shtml",
    "datetime": "2022-02-15 11:32:32",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持11.716万股",
    "href": "http://stock.jrj.com.cn/2022/01/28073334240987.shtml",
    "datetime": "2022-01-28 07:33:32",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获瑞银增持20.84万股",
    "href": "http://stock.jrj.com.cn/2022/01/26083134219480.shtml",
    "datetime": "2022-01-26 08:31:04",
    "code": "603127"
  },
  {
    "title": "昭衍新药2021年预计净利增加约2.28亿-2.59亿同比增加约72%-82% 在手订单高效执行",
    "href": "http://stock.jrj.com.cn/2022/01/20183334179420.shtml",
    "datetime": "2022-01-20 18:33:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2021年净利同比预增72%-82%",
    "href": "http://stock.jrj.com.cn/2022/01/20163934178688.shtml",
    "datetime": "2022-01-20 16:39:55",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)2021年度净利润预增72.3%-82.3%",
    "href": "http://stock.jrj.com.cn/2022/01/20163534178677.shtml",
    "datetime": "2022-01-20 16:35:31",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获Aggregate of abrdn plc增持24.68万股",
    "href": "http://stock.jrj.com.cn/2022/01/12063334148214.shtml",
    "datetime": "2022-01-12 06:33:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持32.81万股",
    "href": "http://stock.jrj.com.cn/2021/12/29083034079568.shtml",
    "datetime": "2021-12-29 08:30:08",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：孙云霞、顾晓磊分别减持21万股、125万股",
    "href": "http://stock.jrj.com.cn/2021/12/01184133950876.shtml",
    "datetime": "2021-12-01 18:41:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：63.31万股行权股票将于12月7日上市流通",
    "href": "http://stock.jrj.com.cn/2021/12/01175833950616.shtml",
    "datetime": "2021-12-01 17:58:48",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：减持期过半 董事孙云霞、顾晓磊已减持合计146.29万股",
    "href": "http://stock.jrj.com.cn/2021/12/01175733950615.shtml",
    "datetime": "2021-12-01 17:57:09",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根士丹利增持6.96万股",
    "href": "http://stock.jrj.com.cn/2021/11/26074733922121.shtml",
    "datetime": "2021-11-26 07:47:50",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭贝莱德减持78.01万股",
    "href": "http://stock.jrj.com.cn/2021/11/25071733917218.shtml",
    "datetime": "2021-11-25 07:17:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药齐低开 董事及其一致行动人拟合计减持不超1.84%公司股份",
    "href": "http://stock.jrj.com.cn/2021/11/22093233902090.shtml",
    "datetime": "2021-11-22 09:32:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：部分董监拟减持合计不超1.84%股份",
    "href": "http://stock.jrj.com.cn/2021/11/19163833880265.shtml",
    "datetime": "2021-11-19 16:38:28",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获Aggregate of abrdn plc增持21.2万股",
    "href": "http://stock.jrj.com.cn/2021/11/16070333858142.shtml",
    "datetime": "2021-11-16 07:03:17",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：减持期届满 监事孙辉业、尹丽莉、李叶合计减持4.75万股",
    "href": "http://stock.jrj.com.cn/2021/11/10164133831944.shtml",
    "datetime": "2021-11-10 16:41:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根大通增持20.43万股",
    "href": "http://stock.jrj.com.cn/2021/11/10073633830355.shtml",
    "datetime": "2021-11-10 07:36:23",
    "code": "603127"
  },
  {
    "title": "利空诱因+高估值！港A两地CRO股持续下挫：昭衍新药和药明生物领跌",
    "href": "http://stock.jrj.com.cn/2021/11/04142633812324.shtml",
    "datetime": "2021-11-04 14:26:11",
    "code": "603127"
  },
  {
    "title": "昭衍新药：前三财季净利2.48亿元，同比增长72.76%",
    "href": "http://stock.jrj.com.cn/2021/11/03091533806886.shtml",
    "datetime": "2021-11-03 09:15:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：第三季度净利润升76.76%至9427.12万元",
    "href": "http://stock.jrj.com.cn/2021/10/29180733778701.shtml",
    "datetime": "2021-10-29 18:07:23",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：27.11万股限售股将于10月27日上市流通",
    "href": "http://stock.jrj.com.cn/2021/10/21181233728489.shtml",
    "datetime": "2021-10-21 18:12:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持5.634万股",
    "href": "http://stock.jrj.com.cn/2021/10/18075733708691.shtml",
    "datetime": "2021-10-18 07:57:14",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根大通增持3.536万股",
    "href": "http://stock.jrj.com.cn/2021/10/13072133683040.shtml",
    "datetime": "2021-10-13 07:21:48",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持3.84万股",
    "href": "http://stock.jrj.com.cn/2021/10/12073533676968.shtml",
    "datetime": "2021-10-12 07:35:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：121.52万股股票期权将于10月13日上市流通",
    "href": "http://stock.jrj.com.cn/2021/09/30202533544834.shtml",
    "datetime": "2021-09-30 20:25:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东左从林减持65.16万股 套现1.06亿 上半年公司净利1.54亿",
    "href": "http://stock.jrj.com.cn/2021/09/29211633538453.shtml",
    "datetime": "2021-09-29 21:16:58",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事左从林完成减持65.16万股",
    "href": "http://stock.jrj.com.cn/2021/09/29205833538319.shtml",
    "datetime": "2021-09-29 20:58:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东顾晓磊、顾美芳累计减持股份达1.08%",
    "href": "http://stock.jrj.com.cn/2021/09/28164833530851.shtml",
    "datetime": "2021-09-28 16:48:42",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东周志文质押214.66万股 用于偿还债务",
    "href": "http://stock.jrj.com.cn/2021/09/24203133511541.shtml",
    "datetime": "2021-09-24 20:31:59",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东周志文质押214.66万股",
    "href": "http://stock.jrj.com.cn/2021/09/24170233510530.shtml",
    "datetime": "2021-09-24 17:02:43",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟以400万至800万元回购A股股份",
    "href": "http://stock.jrj.com.cn/2021/09/21173833487871.shtml",
    "datetime": "2021-09-21 17:38:58",
    "code": "603127"
  },
  {
    "title": "昭衍新药控股股东周志文质押286.21万股 用于偿还债务",
    "href": "http://stock.jrj.com.cn/2021/09/16183933446282.shtml",
    "datetime": "2021-09-16 18:39:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东顾晓磊解质294万股",
    "href": "http://stock.jrj.com.cn/2021/09/16170633445688.shtml",
    "datetime": "2021-09-16 17:06:49",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东周志文质押286.21万股",
    "href": "http://stock.jrj.com.cn/2021/09/16170533445686.shtml",
    "datetime": "2021-09-16 17:05:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东姚大林减持2.29万股 套现352.25万 上半年公司净利1.54亿",
    "href": "http://stock.jrj.com.cn/2021/09/08195433405623.shtml",
    "datetime": "2021-09-08 19:54:19",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：董事姚大林减持2.29万股A股 减持计划实施完毕",
    "href": "http://stock.jrj.com.cn/2021/09/08185733405388.shtml",
    "datetime": "2021-09-08 18:57:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药：董事姚大林减持计划实施完毕 共减持2.29万股公司股份",
    "href": "http://stock.jrj.com.cn/2021/09/08171033404990.shtml",
    "datetime": "2021-09-08 17:10:25",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事姚大林完成减持2.29万股",
    "href": "http://stock.jrj.com.cn/2021/09/08164333404509.shtml",
    "datetime": "2021-09-08 16:43:48",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获瑞银增持4.84万股",
    "href": "http://stock.jrj.com.cn/2021/09/02073933372028.shtml",
    "datetime": "2021-09-02 07:39:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭贝莱德减持28.97万股",
    "href": "http://stock.jrj.com.cn/2021/09/01082133365632.shtml",
    "datetime": "2021-09-01 08:21:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药2021年半年度净利1.54亿元 同比净利增加70.39%",
    "href": "http://stock.jrj.com.cn/2021/08/31122833359908.shtml",
    "datetime": "2021-08-31 12:28:52",
    "code": "603127"
  },
  {
    "title": "昭衍新药对境内相关全资子公司增资",
    "href": "http://stock.jrj.com.cn/invest/2021/08/31110833361402.shtml",
    "datetime": "2021-08-31 11:08:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)拟对境内相关全资子公司增资",
    "href": "http://stock.jrj.com.cn/2021/08/30230533356288.shtml",
    "datetime": "2021-08-30 23:05:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)半年度净利润1.54亿元 同比增长70.39%",
    "href": "http://stock.jrj.com.cn/2021/08/30202633354868.shtml",
    "datetime": "2021-08-30 20:26:57",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根大通增持117.6万股",
    "href": "http://stock.jrj.com.cn/2021/08/27071833330393.shtml",
    "datetime": "2021-08-27 07:18:29",
    "code": "603127"
  },
  {
    "title": "CRO细分龙头昭衍新药涨近6%，医疗ETF（512170）拉升翻红站稳5日均线",
    "href": "http://stock.jrj.com.cn/2021/08/25102933314846.shtml",
    "datetime": "2021-08-25 10:29:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)8月30日举行董事会会议审批中期业绩",
    "href": "http://stock.jrj.com.cn/2021/08/18174833274700.shtml",
    "datetime": "2021-08-18 17:48:23",
    "code": "603127"
  },
  {
    "title": "昭衍新药董事及一致行动人拟合计减持不超520.6万股 上半年公司净利1.49亿-1.58亿",
    "href": "http://stock.jrj.com.cn/2021/08/12194933244438.shtml",
    "datetime": "2021-08-12 19:49:56",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事及一致行动人拟合计减持不超1.37%的股份",
    "href": "http://stock.jrj.com.cn/2021/08/12164233243177.shtml",
    "datetime": "2021-08-12 16:42:58",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年净利润预计同比增长约97%-109%",
    "href": "http://stock.jrj.com.cn/2021/08/10102033230152.shtml",
    "datetime": "2021-08-10 10:20:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药2021年上半年预计净利1.49亿-1.58亿增加97%-109% 承接订单高速增长",
    "href": "http://stock.jrj.com.cn/2021/08/09205933227258.shtml",
    "datetime": "2021-08-09 20:59:55",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)半年度净利润预增97.2%到109.1%",
    "href": "http://stock.jrj.com.cn/2021/08/09165733225882.shtml",
    "datetime": "2021-08-09 16:57:11",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)2020年度A股权益分派10转4派3.5元 股权登记日为8月4日",
    "href": "http://stock.jrj.com.cn/2021/07/29175233170335.shtml",
    "datetime": "2021-07-29 17:52:04",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：减持数量已过半 监事孙辉业减持2万股",
    "href": "http://stock.jrj.com.cn/2021/07/28165133164400.shtml",
    "datetime": "2021-07-28 16:51:40",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：约17.84万股行权股票将于7月22日上市流通",
    "href": "http://stock.jrj.com.cn/2021/07/16172633108198.shtml",
    "datetime": "2021-07-16 17:26:05",
    "code": "603127"
  },
  {
    "title": "港A医药外包概念股全线上涨 龙头昭衍新药H股涨超14%",
    "href": "http://stock.jrj.com.cn/2021/07/14142433094509.shtml",
    "datetime": "2021-07-14 14:24:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)获摩根大通增持18.13万股",
    "href": "http://stock.jrj.com.cn/2021/07/13074133086357.shtml",
    "datetime": "2021-07-13 07:41:33",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭UBS Group AG减持12.08万股",
    "href": "http://stock.jrj.com.cn/2021/07/12074433080737.shtml",
    "datetime": "2021-07-12 07:44:10",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持270万股 套现合计4.78亿",
    "href": "http://stock.jrj.com.cn/2021/06/28211833011950.shtml",
    "datetime": "2021-06-28 21:18:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：顾晓磊及其一致行动人完成减持合计270万股",
    "href": "http://stock.jrj.com.cn/2021/06/28171733010671.shtml",
    "datetime": "2021-06-28 17:17:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：顾晓磊及其一致行动人完成减持合计约270万股",
    "href": "http://stock.jrj.com.cn/2021/06/28170933010613.shtml",
    "datetime": "2021-06-28 17:09:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：公司未来也计划利用AI技术提高试验效率和质量",
    "href": "http://stock.jrj.com.cn/2021/06/23213532985275.shtml",
    "datetime": "2021-06-23 21:35:32",
    "code": "603127"
  },
  {
    "title": "昭衍新药：公司承接过一定的医美相关药物的评价",
    "href": "http://stock.jrj.com.cn/2021/06/21202632971364.shtml",
    "datetime": "2021-06-21 20:26:42",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)参与百克生物IPO战略配售 拟获配120万股",
    "href": "http://stock.jrj.com.cn/2021/06/11172032912141.shtml",
    "datetime": "2021-06-11 17:20:15",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事顾晓磊及一致行动人累计减持135万股",
    "href": "http://stock.jrj.com.cn/2021/06/03170432869749.shtml",
    "datetime": "2021-06-03 17:04:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：股东顾美芳累计减持46.49万股",
    "href": "http://stock.jrj.com.cn/2021/05/24221232812773.shtml",
    "datetime": "2021-05-24 22:12:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东顾美芳及一致行动人持股比例降至9.83%",
    "href": "http://stock.jrj.com.cn/2021/05/24183232811721.shtml",
    "datetime": "2021-05-24 18:32:36",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)遭摩根大通减持2.09万股",
    "href": "http://stock.jrj.com.cn/2021/05/14071032752551.shtml",
    "datetime": "2021-05-14 07:10:49",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持12.42万股 套现合计1870.21万",
    "href": "http://stock.jrj.com.cn/2021/05/13200332750225.shtml",
    "datetime": "2021-05-13 20:03:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)：顾静良和徐洁减持股份达其预期 提前终止减持计划",
    "href": "http://stock.jrj.com.cn/2021/05/13192132749805.shtml",
    "datetime": "2021-05-13 19:21:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：高管顾静良及一致行动人提前终止减持 合计减持12.42万股",
    "href": "http://stock.jrj.com.cn/2021/05/13165932748891.shtml",
    "datetime": "2021-05-13 16:59:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：公司董事姚大林以及监事孙辉业等人员减持的股份主要来源是股权激励授予的股份",
    "href": "http://stock.jrj.com.cn/2021/04/22091632421104.shtml",
    "datetime": "2021-04-22 09:16:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药：公司大部分的试验所需要周期为6-12个月",
    "href": "http://stock.jrj.com.cn/2021/04/22091332421097.shtml",
    "datetime": "2021-04-22 09:13:40",
    "code": "603127"
  },
  {
    "title": "昭衍新药：公司侧重的是药物的非临床安全性评价",
    "href": "http://stock.jrj.com.cn/2021/04/22091332421098.shtml",
    "datetime": "2021-04-22 09:13:31",
    "code": "603127"
  },
  {
    "title": "昭衍新药：董事顾晓磊及其一致行动人拟减持不超总股本1%",
    "href": "http://stock.jrj.com.cn/2021/04/09171232343004.shtml",
    "datetime": "2021-04-09 17:12:34",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事顾晓磊方面拟减持不超1%股份",
    "href": "http://stock.jrj.com.cn/2021/04/09171132342993.shtml",
    "datetime": "2021-04-09 17:11:51",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：2018年激励计划第三个行权/解除限售期行权/解除限售条件成就",
    "href": "http://stock.jrj.com.cn/2021/03/30143532247698.shtml",
    "datetime": "2021-03-30 14:35:42",
    "code": "603127"
  },
  {
    "title": "昭衍新药上市首份成绩单出炉，2020年营收破10亿元，海外订单同比增长约85%",
    "href": "http://stock.jrj.com.cn/2021/03/30115432247118.shtml",
    "datetime": "2021-03-30 11:54:18",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：2020年度净利升68.67%至3.15亿元 拟10转4派3.5元",
    "href": "http://stock.jrj.com.cn/2021/03/29220932243619.shtml",
    "datetime": "2021-03-29 22:09:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药今日获深交所调入港股通股票名单",
    "href": "http://stock.jrj.com.cn/2021/03/22095132190696.shtml",
    "datetime": "2021-03-22 09:51:33",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：部分行使超额配股权、稳定价格行动及稳定价格期结束",
    "href": "http://stock.jrj.com.cn/2021/03/21164732178645.shtml",
    "datetime": "2021-03-21 16:47:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药4名股东合计减持74.57万股 套现合计7719.9万",
    "href": "http://stock.jrj.com.cn/2021/03/12194732122225.shtml",
    "datetime": "2021-03-12 19:47:34",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：4名股东及董监高减持期届满 累计减持74.57万元",
    "href": "http://stock.jrj.com.cn/2021/03/12165932115868.shtml",
    "datetime": "2021-03-12 16:59:19",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东顾美芳质押350万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2021/03/08214032093236.shtml",
    "datetime": "2021-03-08 21:40:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：顾美芳解质及质押均为350万股",
    "href": "http://stock.jrj.com.cn/2021/03/08174332091949.shtml",
    "datetime": "2021-03-08 17:43:08",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：公司H股2月26日起挂牌交易",
    "href": "http://stock.jrj.com.cn/2021/02/26160232033114.shtml",
    "datetime": "2021-02-26 16:02:17",
    "code": "603127"
  },
  {
    "title": "港股IPO|昭衍新药上市低开破发，盘中跌幅逾7%",
    "href": "http://stock.jrj.com.cn/2021/02/26102032031582.shtml",
    "datetime": "2021-02-26 10:20:20",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：H股发行定为每股151港币 明起在联交所挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/02/25214532028033.shtml",
    "datetime": "2021-02-25 21:45:28",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：H股的发行价区间初步确定为133-151港元",
    "href": "http://stock.jrj.com.cn/2021/02/17172731975020.shtml",
    "datetime": "2021-02-17 17:27:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(06127.HK)拟全球发售4332.48万股 引入清池资本等多家基石",
    "href": "http://stock.jrj.com.cn/2021/02/16063831950925.shtml",
    "datetime": "2021-02-16 06:38:07",
    "code": "603127"
  },
  {
    "title": "舒泰神(300204.SZ)拟与昭衍新药签署销售框架协议和研发服务框架协议",
    "href": "http://stock.jrj.com.cn/2021/02/09190131878698.shtml",
    "datetime": "2021-02-09 19:01:52",
    "code": "603127"
  },
  {
    "title": "昭衍新药4年净利复合增长率超50% 引领国内CRO股价累计上涨34倍",
    "href": "http://stock.jrj.com.cn/2021/02/04081231846637.shtml",
    "datetime": "2021-02-04 08:12:12",
    "code": "603127"
  },
  {
    "title": "港股IPO|昭衍新药已聆讯通过，期内毛利率均超过50%",
    "href": "http://stock.jrj.com.cn/2021/02/01152831830005.shtml",
    "datetime": "2021-02-01 15:28:57",
    "code": "603127"
  },
  {
    "title": "港股IPO|传昭衍新药预计最快本周进行上市聆讯，募资约5亿至6亿美元",
    "href": "http://stock.jrj.com.cn/2021/01/27102131786916.shtml",
    "datetime": "2021-01-27 10:21:15",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持225.8万股 套现合计2.55亿",
    "href": "http://stock.jrj.com.cn/2021/01/25221531769284.shtml",
    "datetime": "2021-01-25 22:15:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：实控人冯宇霞解质850.7296万股",
    "href": "http://stock.jrj.com.cn/2021/01/22185231746607.shtml",
    "datetime": "2021-01-22 18:52:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：首次公开发行境外上市外资股获中国证监会批复",
    "href": "http://stock.jrj.com.cn/2021/01/21161331736999.shtml",
    "datetime": "2021-01-21 16:13:48",
    "code": "603127"
  },
  {
    "title": "A股异动丨昭衍新药(603127.SH)一字涨停 2020年度净利润预增约69.9%到80.3%",
    "href": "http://stock.jrj.com.cn/2021/01/20093731726356.shtml",
    "datetime": "2021-01-20 09:37:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：募投项目“建设药物临床前研究基地项目”结项",
    "href": "http://stock.jrj.com.cn/2021/01/19222331724133.shtml",
    "datetime": "2021-01-19 22:23:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)2020年度净利润预增约69.9%到80.3%",
    "href": "http://stock.jrj.com.cn/2021/01/19222131724127.shtml",
    "datetime": "2021-01-19 22:21:45",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持50.54万股 套现合计约5100.22万元",
    "href": "http://stock.jrj.com.cn/2020/12/31195631614330.shtml",
    "datetime": "2020-12-31 19:56:28",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事孙云霞减持50.04万股 姚大林减持5000股 减持完毕",
    "href": "http://stock.jrj.com.cn/2020/12/31172131613195.shtml",
    "datetime": "2020-12-31 17:21:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东高大鹏减持2.4万股 套现约245.67万元",
    "href": "http://stock.jrj.com.cn/2020/12/28191431587900.shtml",
    "datetime": "2020-12-28 19:14:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事高大鹏减持完毕 累计减持2.4万股",
    "href": "http://stock.jrj.com.cn/2020/12/28163931586716.shtml",
    "datetime": "2020-12-28 16:39:22",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事姚大林减持期过半 累计减持1000股",
    "href": "http://stock.jrj.com.cn/2020/12/21164131536805.shtml",
    "datetime": "2020-12-21 16:41:42",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：实控人冯宇霞1781.23万股质押延期",
    "href": "http://stock.jrj.com.cn/2020/12/18174931519555.shtml",
    "datetime": "2020-12-18 17:49:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：董事高大鹏、监事尹丽莉已合计减持2.45万股",
    "href": "http://stock.jrj.com.cn/2020/12/16174231503245.shtml",
    "datetime": "2020-12-16 17:42:58",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：5名股东及董监高减持期过半 累计减持37.05万股",
    "href": "http://stock.jrj.com.cn/2020/12/15172931495282.shtml",
    "datetime": "2020-12-15 17:29:05",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东顾晓磊质押350万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2020/12/10193731458811.shtml",
    "datetime": "2020-12-10 19:37:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东顾晓磊质押210万股 用于自身生产经营",
    "href": "http://stock.jrj.com.cn/2020/12/01194331386445.shtml",
    "datetime": "2020-12-01 19:43:31",
    "code": "603127"
  },
  {
    "title": "昭衍新药(603127.SH)：股东顾晓磊质押210万股",
    "href": "http://stock.jrj.com.cn/2020/12/01161231385258.shtml",
    "datetime": "2020-12-01 16:12:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药：近几年年 动物销售占比均不到5%",
    "href": "http://stock.jrj.com.cn/2020/11/27092131357786.shtml",
    "datetime": "2020-11-27 09:21:55",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东左从林减持16.58万股 套现约1701.69万元",
    "href": "http://stock.jrj.com.cn/2020/11/25190431347563.shtml",
    "datetime": "2020-11-25 19:04:35",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年股票期权与限制性股票激励计划股票期权第一次行权结果暨股份上市的公告",
    "href": "http://stock.jrj.com.cn/2020/11/10001031243997.shtml",
    "datetime": "2020-11-10 00:10:01",
    "code": "603127"
  },
  {
    "title": "昭衍新药跌9% 华夏未来汇添富等机构为前十流通股东",
    "href": "http://stock.jrj.com.cn/2020/11/02165631201501.shtml",
    "datetime": "2020-11-02 16:56:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药前三季度净利1.18亿增长53.19% 业务量增长及收购BIOMERE",
    "href": "http://stock.jrj.com.cn/2020/11/01120931183277.shtml",
    "datetime": "2020-11-01 12:09:11",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年股票期权与限制性股票激励计划限制性股票第一次解除限售暨上市的公告",
    "href": "http://stock.jrj.com.cn/2020/10/24001031119701.shtml",
    "datetime": "2020-10-24 00:10:32",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东合计减持225.99万股 套现约2.09亿元",
    "href": "http://stock.jrj.com.cn/2020/09/28194830854705.shtml",
    "datetime": "2020-09-28 19:48:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东孙辉业减持4.1万股 套现约374.34万元",
    "href": "http://stock.jrj.com.cn/2020/09/25203730837331.shtml",
    "datetime": "2020-09-25 20:37:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2020年第四次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/09/16001030757723.shtml",
    "datetime": "2020-09-16 00:10:20",
    "code": "603127"
  },
  {
    "title": "舒泰神实控人周志文遭监管谈话 违规关联交易昭衍新药",
    "href": "http://stock.jrj.com.cn/2020/09/08155730704058.shtml",
    "datetime": "2020-09-08 15:57:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东孙云霞减持3.49万股 套现约365.34万元",
    "href": "http://stock.jrj.com.cn/2020/09/03202030670410.shtml",
    "datetime": "2020-09-03 20:20:47",
    "code": "603127"
  },
  {
    "title": "昭衍新药2020年上半年净利7566.48万增长87.17% 业务量增长",
    "href": "http://stock.jrj.com.cn/2020/08/31201830645361.shtml",
    "datetime": "2020-08-31 20:18:42",
    "code": "603127"
  },
  {
    "title": "[加急]8月最大解禁潮来袭 韦尔股份领衔 昭衍新药、长亮科技跻身十倍股",
    "href": "http://stock.jrj.com.cn/2020/08/23113730564432.shtml",
    "datetime": "2020-08-23 11:37:22",
    "code": "603127"
  },
  {
    "title": "昭衍新药对外投资设立子公司并取得营业执照 注册资本2000万元",
    "href": "http://stock.jrj.com.cn/invest/2020/08/05083430429935.shtml",
    "datetime": "2020-08-05 08:34:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药对外投资设立子公司并取得营业执照 注册资本2000万元",
    "href": "http://stock.jrj.com.cn/invest/2020/08/05083430541712.shtml",
    "datetime": "2020-08-05 08:34:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药向激励对象授予209万份股票期权",
    "href": "http://stock.jrj.com.cn/invest/2020/07/20103430291645.shtml",
    "datetime": "2020-07-20 10:34:00",
    "code": "603127"
  },
  {
    "title": "舒泰神豁免议案遭问询 违背原承诺与昭衍新药关联交易",
    "href": "http://stock.jrj.com.cn/2020/07/15155530250526.shtml",
    "datetime": "2020-07-15 15:55:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]北方片区毒性病理第十一届读片会(网络)圆满成功",
    "href": "http://stock.jrj.com.cn/2020/06/24000031623929.shtml",
    "datetime": "2020-06-24 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东高大鹏减持3.14万股 套现约356.1万元",
    "href": "http://stock.jrj.com.cn/2020/06/04193429846247.shtml",
    "datetime": "2020-06-04 19:34:46",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东姚大林减持1.73万股 套现约174.76万元",
    "href": "http://stock.jrj.com.cn/2020/05/26175729769561.shtml",
    "datetime": "2020-05-26 17:57:50",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于2018年股票期权与限制性股票激励计划股票期权第二次行权结果暨股份上市的公告",
    "href": "http://stock.jrj.com.cn/2020/05/21234029734022.shtml",
    "datetime": "2020-05-21 23:40:04",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东左从林减持3.14万股 套现约323.93万元",
    "href": "http://stock.jrj.com.cn/2020/05/13211929663745.shtml",
    "datetime": "2020-05-13 21:19:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/05/12232029653892.shtml",
    "datetime": "2020-05-12 23:20:04",
    "code": "603127"
  },
  {
    "title": "昭衍新药4900万元购买理财产品",
    "href": "http://stock.jrj.com.cn/invest/2020/05/06084129641398.shtml",
    "datetime": "2020-05-06 08:41:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：以闲置自有资金4900万元购买招商银行理财产品 提高资金收益",
    "href": "http://stock.jrj.com.cn/2020/05/05194129577019.shtml",
    "datetime": "2020-05-05 19:41:33",
    "code": "603127"
  },
  {
    "title": "昭衍新药2020年一季度净利1914.7万增长59.03% 业务量增长及收购BIOMERE所致",
    "href": "http://stock.jrj.com.cn/2020/05/01122629439191.shtml",
    "datetime": "2020-05-01 12:26:23",
    "code": "603127"
  },
  {
    "title": "业绩预增股受到资金追捧 昭衍新药等10余股涨停",
    "href": "http://stock.jrj.com.cn/2020/04/14131629282383.shtml",
    "datetime": "2020-04-14 13:16:26",
    "code": "603127"
  },
  {
    "title": "赊账的买卖靠不住！昭衍新药营收增长五成 应收账款增加1.7倍",
    "href": "http://stock.jrj.com.cn/2020/04/13091129273009.shtml",
    "datetime": "2020-04-13 09:11:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药4名股东拟减持股份 预计合计减持不超总股本0.1%",
    "href": "http://stock.jrj.com.cn/2020/04/12205629264745.shtml",
    "datetime": "2020-04-12 20:56:27",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2020/04/12194029264603.shtml",
    "datetime": "2020-04-12 19:40:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十六次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/04/12194029264602.shtml",
    "datetime": "2020-04-12 19:40:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年年度股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/04/12194029264601.shtml",
    "datetime": "2020-04-12 19:40:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年度净利润同比增长近65% 拟10转4派3.4",
    "href": "http://stock.jrj.com.cn/2020/04/12141529264006.shtml",
    "datetime": "2020-04-12 14:15:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]新型冠状病毒潜在治疗药物——阿比多尔",
    "href": "http://stock.jrj.com.cn/2020/02/24000030648227.shtml",
    "datetime": "2020-02-24 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东顾晓磊减持40万股 套现约2911万元",
    "href": "http://stock.jrj.com.cn/2020/02/20195428864104.shtml",
    "datetime": "2020-02-20 19:54:16",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍剿冠突击队",
    "href": "http://stock.jrj.com.cn/2020/02/16000030648225.shtml",
    "datetime": "2020-02-16 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：加速研发抗击新型冠状病毒药品",
    "href": "http://stock.jrj.com.cn/2020/02/12140428815199.shtml",
    "datetime": "2020-02-12 14:04:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药拟使用7000万闲置资金进行理财",
    "href": "http://stock.jrj.com.cn/2020/02/12111628814484.shtml",
    "datetime": "2020-02-12 11:16:37",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟购买7000万元理财产品 提高相关资金使用效率",
    "href": "http://stock.jrj.com.cn/2020/02/11174128810210.shtml",
    "datetime": "2020-02-11 17:41:07",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]新型冠状病毒(2019-nCoV) 潜在治疗药物",
    "href": "http://stock.jrj.com.cn/2020/02/10000030648232.shtml",
    "datetime": "2020-02-10 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2020年第一次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2020/02/07221028795342.shtml",
    "datetime": "2020-02-07 22:10:02",
    "code": "603127"
  },
  {
    "title": "昭衍新药：针对疫情正配合医药研发机构工作 并开通绿色通道",
    "href": "http://stock.jrj.com.cn/2020/02/06105228782684.shtml",
    "datetime": "2020-02-06 10:52:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]新型冠状病毒(2019-nCoV)结构及感染宿主细胞机制",
    "href": "http://stock.jrj.com.cn/2020/02/03000030648231.shtml",
    "datetime": "2020-02-03 00:00:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍新药致药物研发企业及昭衍同仁的一封",
    "href": "http://stock.jrj.com.cn/2020/02/02000030648223.shtml",
    "datetime": "2020-02-02 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十五次会议决议公告",
    "href": "http://stock.jrj.com.cn/2020/01/21074028710768.shtml",
    "datetime": "2020-01-21 07:40:14",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2020年第一次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2020/01/21074028710767.shtml",
    "datetime": "2020-01-21 07:40:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟参与竞拍上海斯莱克80%股权",
    "href": "http://stock.jrj.com.cn/2020/01/20182628707039.shtml",
    "datetime": "2020-01-20 18:26:29",
    "code": "603127"
  },
  {
    "title": "2019年度净利同比预增40%-60% 昭衍新药涨停",
    "href": "http://stock.jrj.com.cn/2020/01/09101028648197.shtml",
    "datetime": "2020-01-09 10:10:06",
    "code": "603127"
  },
  {
    "title": "昭衍新药2019年预计盈利1.52亿元至1.73亿元",
    "href": "http://stock.jrj.com.cn/2020/01/09095528648176.shtml",
    "datetime": "2020-01-09 09:55:14",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年业绩预增公告",
    "href": "http://stock.jrj.com.cn/2020/01/09003028646012.shtml",
    "datetime": "2020-01-09 00:30:01",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2020/01/08220028645687.shtml",
    "datetime": "2020-01-08 22:00:01",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年度净利同比预增40%-60%",
    "href": "http://stock.jrj.com.cn/2020/01/08184928644972.shtml",
    "datetime": "2020-01-08 18:49:39",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年净利预增40%到60%",
    "href": "http://stock.jrj.com.cn/2020/01/08184428644970.shtml",
    "datetime": "2020-01-08 18:44:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]2020新年快乐!",
    "href": "http://stock.jrj.com.cn/2019/12/31000030102850.shtml",
    "datetime": "2019-12-31 00:00:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]祝贺昂科免疫(Oncoimmune Inc.)I类新药ONC-392获美国FDA批准开展临床试验!",
    "href": "http://stock.jrj.com.cn/2019/12/31000030406792.shtml",
    "datetime": "2019-12-31 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药2名股东拟减持股份 预计合计减持不超总股本0.44%",
    "href": "http://stock.jrj.com.cn/2019/12/17220428547837.shtml",
    "datetime": "2019-12-17 22:04:28",
    "code": "603127"
  },
  {
    "title": "昭衍新药：董事及其一致行动人拟集中竞价减持0.44％股份",
    "href": "http://stock.jrj.com.cn/2019/12/17163028546515.shtml",
    "datetime": "2019-12-17 16:30:26",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第七次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/12/11230028521647.shtml",
    "datetime": "2019-12-11 23:00:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十四次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/12/11230028521648.shtml",
    "datetime": "2019-12-11 23:00:38",
    "code": "603127"
  },
  {
    "title": "昭衍新药拟11亿元投建昭衍（广州）新药评价中心项目",
    "href": "http://stock.jrj.com.cn/2019/12/11175028520197.shtml",
    "datetime": "2019-12-11 17:50:57",
    "code": "603127"
  },
  {
    "title": "昭衍新药：投资11亿建设昭衍（广州）新药评价中心项目",
    "href": "http://stock.jrj.com.cn/2019/12/11172828520084.shtml",
    "datetime": "2019-12-11 17:28:26",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟投建新药评价中心项目 扩大华南地区医药研发外包服务范围",
    "href": "http://stock.jrj.com.cn/2019/12/11164028519847.shtml",
    "datetime": "2019-12-11 16:40:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟11亿元投建昭衍（广州）新药评价中心项目",
    "href": "http://stock.jrj.com.cn/2019/12/11163328519842.shtml",
    "datetime": "2019-12-11 16:33:37",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]开启新征程,迈入新格局 ——昭衍新药完成对美国Biomere的收购",
    "href": "http://stock.jrj.com.cn/2019/12/11000030102849.shtml",
    "datetime": "2019-12-11 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第六次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/12/05011028491028.shtml",
    "datetime": "2019-12-05 01:10:04",
    "code": "603127"
  },
  {
    "title": "昭衍新药投资参股通化中检分析测试服务有限公司",
    "href": "http://stock.jrj.com.cn/2019/11/19130828418195.shtml",
    "datetime": "2019-11-19 13:08:55",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第六次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/11/18233028415149.shtml",
    "datetime": "2019-11-18 23:30:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十三次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/11/18233028415150.shtml",
    "datetime": "2019-11-18 23:30:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第五次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/11/16024028407161.shtml",
    "datetime": "2019-11-16 02:40:14",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]圆满结束2019国际眼科新药研发暨转化医学学术研讨会(2019 ITRO)",
    "href": "http://stock.jrj.com.cn/2019/11/12000029809917.shtml",
    "datetime": "2019-11-12 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药前三季度盈利7648万 同比增长34%",
    "href": "http://stock.jrj.com.cn/2019/10/31115628332566.shtml",
    "datetime": "2019-10-31 11:56:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年前三季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/10/31015028329504.shtml",
    "datetime": "2019-10-31 01:50:18",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第五次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/10/31015028329502.shtml",
    "datetime": "2019-10-31 01:50:18",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十二次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/10/31015028329503.shtml",
    "datetime": "2019-10-31 01:50:18",
    "code": "603127"
  },
  {
    "title": "昭衍新药4名股东合计减持161万股 套现约1.02亿元",
    "href": "http://stock.jrj.com.cn/2019/09/29180828197020.shtml",
    "datetime": "2019-09-29 18:08:34",
    "code": "603127"
  },
  {
    "title": "昭衍新药以自有资金2000万元认购理财产品",
    "href": "http://stock.jrj.com.cn/2019/09/18204528149915.shtml",
    "datetime": "2019-09-18 20:45:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第十次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/09/09224028111560.shtml",
    "datetime": "2019-09-09 22:40:10",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]全面获得医疗器械评价资质——昭衍(苏州)通过CNAS监督评审",
    "href": "http://stock.jrj.com.cn/2019/09/02000029163664.shtml",
    "datetime": "2019-09-02 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第四次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/08/15235027983918.shtml",
    "datetime": "2019-08-15 23:50:10",
    "code": "603127"
  },
  {
    "title": "昭衍新药拟使用6000万闲置募集资金进行现金管理",
    "href": "http://stock.jrj.com.cn/2019/08/13082827967976.shtml",
    "datetime": "2019-08-13 08:28:29",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年半年度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/08/13004027964672.shtml",
    "datetime": "2019-08-13 00:40:17",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第九次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/08/13004027964671.shtml",
    "datetime": "2019-08-13 00:40:17",
    "code": "603127"
  },
  {
    "title": "昭衍新药2019年上半年净利4014万 业务量增长",
    "href": "http://stock.jrj.com.cn/2019/08/12184527963696.shtml",
    "datetime": "2019-08-12 18:45:21",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年净利4014万元 同比增79%",
    "href": "http://stock.jrj.com.cn/2019/08/12174227963276.shtml",
    "datetime": "2019-08-12 17:42:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年净利逾4000万元 同比增长78.86％",
    "href": "http://stock.jrj.com.cn/2019/08/12174127963265.shtml",
    "datetime": "2019-08-12 17:41:11",
    "code": "603127"
  },
  {
    "title": "昭衍新药：上半年净利4014万元 同比增长79%",
    "href": "http://stock.jrj.com.cn/2019/08/12172827963120.shtml",
    "datetime": "2019-08-12 17:28:22",
    "code": "603127"
  },
  {
    "title": "昭衍新药认购8000万理财产品",
    "href": "http://stock.jrj.com.cn/2019/08/09083027951986.shtml",
    "datetime": "2019-08-09 08:30:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药全资子公司以自有资金5000万元认购步增盈安心版理财产品",
    "href": "http://stock.jrj.com.cn/2019/08/07082027941160.shtml",
    "datetime": "2019-08-07 08:20:21",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第四次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/07/30013027901219.shtml",
    "datetime": "2019-07-30 01:30:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第八次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/07/30013027901220.shtml",
    "datetime": "2019-07-30 01:30:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东拟减持股份 预计减持不超总股本1%",
    "href": "http://stock.jrj.com.cn/2019/07/26072827889470.shtml",
    "datetime": "2019-07-26 07:28:54",
    "code": "603127"
  },
  {
    "title": "昭衍新药：董事顾晓磊及其一致人拟减持不超1％股份",
    "href": "http://stock.jrj.com.cn/2019/07/25212627888226.shtml",
    "datetime": "2019-07-25 21:26:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药：合计持股15.43%的董事及其一致行动人拟减持不超1%",
    "href": "http://stock.jrj.com.cn/2019/07/25185027887727.shtml",
    "datetime": "2019-07-25 18:50:13",
    "code": "603127"
  },
  {
    "title": "昭衍新药：董事及其一致行动人拟减持不超1%股份",
    "href": "http://stock.jrj.com.cn/2019/07/25183827887685.shtml",
    "datetime": "2019-07-25 18:38:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第三次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/07/18002027854204.shtml",
    "datetime": "2019-07-18 00:20:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第七次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/07/02012027780526.shtml",
    "datetime": "2019-07-02 01:20:02",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第三次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/07/02012027780525.shtml",
    "datetime": "2019-07-02 01:20:02",
    "code": "603127"
  },
  {
    "title": "昭衍新药董事一致行动人拉萨香塘减持151万股 套现约7272万元",
    "href": "http://stock.jrj.com.cn/2019/06/27072927761992.shtml",
    "datetime": "2019-06-27 07:29:50",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于2018年股票期权与限制性股票激励计划股票期权第一次行权结果暨股份上市的公告",
    "href": "http://stock.jrj.com.cn/2019/06/05001027664295.shtml",
    "datetime": "2019-06-05 00:10:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第二次临时股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/05/21222027603248.shtml",
    "datetime": "2019-05-21 22:20:03",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第六次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/05/18131027589045.shtml",
    "datetime": "2019-05-18 13:10:12",
    "code": "603127"
  },
  {
    "title": "昭衍新药首次海外并购 拟2728万美元收购美国同行",
    "href": "http://stock.jrj.com.cn/2019/05/17222827587970.shtml",
    "datetime": "2019-05-17 22:28:30",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟投资设立控股子公司启辰生物",
    "href": "http://stock.jrj.com.cn/2019/05/17180627587217.shtml",
    "datetime": "2019-05-17 18:06:58",
    "code": "603127"
  },
  {
    "title": "昭衍新药拟2728万美元收购美国Biomere公司",
    "href": "http://stock.jrj.com.cn/2019/05/17175927587166.shtml",
    "datetime": "2019-05-17 17:59:27",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟2728万美元收购美国Biomere公司",
    "href": "http://stock.jrj.com.cn/2019/05/17175427587168.shtml",
    "datetime": "2019-05-17 17:54:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：拟2728万美元收购Biomer100%股权",
    "href": "http://stock.jrj.com.cn/2019/05/17174927587117.shtml",
    "datetime": "2019-05-17 17:49:53",
    "code": "603127"
  },
  {
    "title": "昭衍新药一季度净利1204万元同比增长37% 现金流量净额为1625万元",
    "href": "http://stock.jrj.com.cn/2019/05/05131227523906.shtml",
    "datetime": "2019-05-05 13:12:42",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第五次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/04/30102027512575.shtml",
    "datetime": "2019-04-30 10:20:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于召开2019年第二次临时股东大会的通知",
    "href": "http://stock.jrj.com.cn/2019/04/30102027512576.shtml",
    "datetime": "2019-04-30 10:20:24",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2019年第一季度主要财务指标",
    "href": "http://stock.jrj.com.cn/2019/04/30102027512574.shtml",
    "datetime": "2019-04-30 10:20:23",
    "code": "603127"
  },
  {
    "title": "昭衍新药：关于2018年股票期权与限制性股票激励计划限制性股票第一次解除限售暨上市的公告",
    "href": "http://stock.jrj.com.cn/2019/04/23231027469460.shtml",
    "datetime": "2019-04-23 23:10:02",
    "code": "603127"
  },
  {
    "title": "昭衍新药：第三届董事会第四次会议决议公告",
    "href": "http://stock.jrj.com.cn/2019/04/16011027401169.shtml",
    "datetime": "2019-04-16 01:10:07",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍热点药物安全性评价沙龙",
    "href": "http://stock.jrj.com.cn/2019/04/15000028068924.shtml",
    "datetime": "2019-04-15 00:00:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍将参加2019年视觉与眼科研究协会年会(ARVO)",
    "href": "http://stock.jrj.com.cn/2019/04/03000028068922.shtml",
    "datetime": "2019-04-03 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年年度权益分派实施公告",
    "href": "http://stock.jrj.com.cn/2019/04/02003027298206.shtml",
    "datetime": "2019-04-02 00:30:02",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍(梧州)实验动物及药物评价基地建设举行开工仪式",
    "href": "http://stock.jrj.com.cn/2019/04/01000028068920.shtml",
    "datetime": "2019-04-01 00:00:00",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]服务药物创新,专注药物全生命周期的安全性评价与监测——昭衍新药西南中心落户重庆",
    "href": "http://stock.jrj.com.cn/2019/03/30000028068921.shtml",
    "datetime": "2019-03-30 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年年度股东大会决议公告",
    "href": "http://stock.jrj.com.cn/2019/03/23000027211112.shtml",
    "datetime": "2019-03-23 00:00:15",
    "code": "603127"
  },
  {
    "title": "[昭衍新药]昭衍新药顺利通过美国FDA的第四次GLP检查",
    "href": "http://stock.jrj.com.cn/2019/03/18000028068919.shtml",
    "datetime": "2019-03-18 00:00:00",
    "code": "603127"
  },
  {
    "title": "昭衍新药：年利润增长四成多 能否支撑70多倍市盈率？",
    "href": "http://stock.jrj.com.cn/2019/03/07070927129513.shtml",
    "datetime": "2019-03-07 07:09:51",
    "code": "603127"
  },
  {
    "title": "昭衍新药股东拉萨香塘拟减持不超1%股份",
    "href": "http://stock.jrj.com.cn/2019/03/05184927123002.shtml",
    "datetime": "2019-03-05 18:49:03",
    "code": "603127"
  },
  {
    "title": "[互动]昭衍新药：在手订单金额截止2018年底为8亿",
    "href": "http://stock.jrj.com.cn/2019/03/05154127120991.shtml",
    "datetime": "2019-03-05 15:41:41",
    "code": "603127"
  },
  {
    "title": "上市公司业绩精选：昭衍新药2018年净利同比增42%",
    "href": "http://stock.jrj.com.cn/2019/03/01222727107789.shtml",
    "datetime": "2019-03-01 22:27:08",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年净利1.08亿元 拟10转4派3元",
    "href": "http://stock.jrj.com.cn/2019/03/01203827107598.shtml",
    "datetime": "2019-03-01 20:38:20",
    "code": "603127"
  },
  {
    "title": "昭衍新药年报净利同比增长42% 拟10转4派3元",
    "href": "http://stock.jrj.com.cn/2019/03/01203727109422.shtml",
    "datetime": "2019-03-01 20:37:52",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年净利同比增42% 拟10转4派3元",
    "href": "http://stock.jrj.com.cn/2019/03/01184427107352.shtml",
    "datetime": "2019-03-01 18:44:31",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年年度业绩报告预告",
    "href": "http://stock.jrj.com.cn/2019/01/31020027005095.shtml",
    "datetime": "2019-01-31 02:00:14",
    "code": "603127"
  },
  {
    "title": "昭衍新药：2018年业绩预增公告",
    "href": "http://stock.jrj.com.cn/2019/01/31010127004923.shtml",
    "datetime": "2019-01-31 01:01:17",
    "code": "603127"
  }
]